-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Q32 Bio, Raises Price Target to $40

Benzinga·07/13/2026 15:03:03
语音播报
Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the price target from $20 to $40.